-

03:42:37 PM

SNY Stock News

SNY - Sanofi

08/12/22 11:00 AM

Nasdaq : SNY

Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations

Vaccine fatigue may continue to be a barrier to the upcoming flu season Black Americans are less likely to get a flu vaccine compared to white Americans, increasing risk of flu-related complications or hospitalizations 1 People over 65 account for majority of flu-related hospitalizations and deaths

RHEA-AI

negative

08/12/22 9:05 AM

Nasdaq : SNY

clinical trial

NIHR and Sanofi Announce First Patient Enrolled in Large European Clinical Study to Investigate Protection Against RSV, the Leading Cause of Infant Hospitalisation Worldwide

Sanofi and the National Institute for Health and Care Research have today announced that the first patient has been enrolled in the H ospit a lised R SV Mon oclonal Ant i body Pr e vention study. The study has been developed as a collaboration between NIHR, investigators, Sanofi and its clinical research organisation partner, Labcorp. More than 20,000 infants...

RHEA-AI

neutral

08/03/22 2:53 PM

Nasdaq : SNY

management

Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of

RHEA-AI

neutral

07/26/22 7:00 AM

Nasdaq : SNY

partnership

Sanofi partners with Howard University in an unprecedented pharmacy fellowship program

As part of its ongoing efforts to address disparities in underrepresented communities, Sanofi has announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program. Sanofi's

RHEA-AI

very positive

07/01/22 5:04 PM

Nasdaq : SNY

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+

* Fluzone ® High-Dose Quadrivalent (Influenza Vaccine) and Flublok ® Quadrivalent (Influenza Vaccine) are the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators as assessed in randomized controlled trials, the

RHEA-AI

neutral

06/07/22 4:44 PM

Nasdaq : SNY, REGN

fda approval

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trialLong-term safety data from a 52-week open-label extension trial in

RHEA-AI

neutral

06/07/22 8:30 AM

Nasdaq : SNY

Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing

2,500 Sanofi Massachusetts-based employees come together in a shared space to improve collaboration while growing our science-centered, patient-focused culture Single integrated campus supports Play to Win strategy to focus on growth, lead with innovation, accelerate efficiencies, and reinvent the

RHEA-AI

very positive

05/31/22 12:59 AM

Nasdaq : REGN, SNY

FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approvedRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration

RHEA-AI

neutral

05/20/22 3:15 PM

Nasdaq : REGN, SNY

fda approval

FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action dateDupixent 300 mg weekly significantly improved signs and

RHEA-AI

positive

04/13/22 5:00 AM

Nasdaq : SNY

Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi Medications

Today, Sempre Health announced compelling outcomes achieved during the first year of its collaboration with Sanofi (Nasdaq: SNY), an innovative global healthcare

RHEA-AI

positive

SNY Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.sanofi.com
CeoOlivier Brandicourt
Security nameSanofi - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees99412
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address54 Rue la Boetie
StateIle De France
CityParis
Zip75008
CountryFrance
Phone33153774000

About Sanofi

La vocation de Sanofi est d'accompagner celles et ceux confrontés à des difficultés de santé. Entreprise biopharmaceutique mondiale spécialisée dans la santé humaine qui prévient les maladies avec ses vaccins et propose des traitements innovants. Elle accompagne tant ceux qui sont atteints de maladies rares, que les millions de personnes souffrant d'une maladie chronique. Sanofi et ses plus de 100 000 collaborateurs dans 100 pays transforment l'innovation scientifique en solutions de santé partout dans le monde. Sanofi, Empowering Life, donner toute sa force à la vie.